Longevity.

Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and regulating immune responses, which can further damage retinal cells. The company’s lead compound, ONL1204, is a first-in-class small molecule Fas inhibitor, designed to protect key retinal cells, including photoreceptors, from Fas-induced cell death, a primary cause of vision loss in a range of conditions. By targeting Fas signaling, ONL aims to address both the direct and inflammatory pathways leading to cell death, potentially offering a broad therapeutic benefit across a range of retinal diseases. The funding will be used to initiate a global Phase 2 study in patients suffering from geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).…

Collaboration aims to empower health practitione

TVM Capital Healthcare has announced a strategic

Probiotics are often viewed as the solution to v

A recent study highlights that the “pregnancy

Coya Therapeutics is pioneering multi-pathway th

Elon Musk claims that experimental ‘Blindsight

Achieving glowing skin is a goal for many, and c

Longevity.

A new study published in

Boosting cellular regeneration, reducing inflamm

Different diets have been linked to promoting he

Finding purpose and balance often feels elusive

Chai Discovery emerges with $30m in funding and

Can a simple drink help you shed those stubborn

Longevity.

Zurich-based venture capital firm Ayun has launch

A new study considers epigenetic aging from a si

A recent study published in

Imagine discovering that a popular supplement yo

Longevity.

A2C Anti-Aging Clinic in Prague is celebrating it

A recent

A recent study published in

Preventive health company appoints former Amazon

Ahead of Longevity Investors Conference, Matt Py

What if you could shape the future of your brain

Longevity.

A recent study published in

Company integrates generative biology, chemistry

Curious if green tea extract could harm your hea

Longevity.

Ahead of Longevity Investors Conference, Andrea

Curcumin, a compound found in

New research suggests that voice patterns could

Project aims to scale production of induced plur

Longevity.

Longevity company builder Maximon spawns new ven

A new study suggests that having a clear sense o

Daisuke Hori, a 40-year-old Japanese father, has

TimePie’s Hebe Chen spotlights the upcoming fi

In the pursuit of a balanced and fulfilling life